DexCom Inc. (NASDAQ:DXCM) has a beta of 0.75, a 12-month trailing P/E ratio of 67.12, and a growth ratio of 2.84. The stock’s Relative Strength Index (RSI) is 34.20, with weekly volatility at 4.21% and ATR at 13.06. The DXCM stock’s 52-week price range has touched low of $305.63 and a $456.23 high. Its shares traded higher over the last trading session, gaining 1.55% on 05/11/21. The shares fell to a low of $336.18 before closing at $348.00. Intraday shares traded counted 1.57 million, which was -98.64% lower than its 30-day average trading volume of 788.55K. DXCM’s previous close was $342.69 while the outstanding shares total 96.30M.
Investors have identified the Diagnostics & Research company DexCom Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $33.52 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
DexCom Inc. (DXCM) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 3.45 billion total, with 604.1 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 3.29 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on DXCM sounds very interesting.
Is the stock of DXCM attractive?
In related news, Chairman, CEO & President, SAYER KEVIN R sold 5,535 shares of the company’s stock in a transaction that recorded on May 03. The sale was performed at an average price of 379.88, for a total value of 2,102,626. As the sale deal closes, the EVP, Chief Legal Officer, Murphy Patrick Michael now sold 500 shares of the company’s stock, valued at 207,915. Also, Managing Dir., Dexcom Ventures, Pacelli Steven Robert sold 1,079 shares of the company’s stock in a deal that was recorded on Apr 23. The shares were price at an average price of 410.31 per share, with a total market value of 442,727. Following this completion of acquisition, the EVP, Global Revenue, Flynn Paul R now holds 758 shares of the company’s stock, valued at 303,200. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.70%.
15 out of 22 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on DexCom Inc.. 1 analysts has assigned a Sell rating on the DXCM stock. The 12-month mean consensus price target for the company’s shares has been set at $474.21.